Main Menu

NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Oryzon Genomics S.A (MC: ORY)

 
ORY Technical Analysis
5
As on 21st Nov 2024 ORY STOCK Price closed @ 1.57 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 2.00 & Strong Sell for SHORT-TERM with Stoploss of 2.08 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

ORYSTOCK Price

Open 1.58 Change Price %
High 1.60 1 Day -0.01 -0.63
Low 1.55 1 Week -0.13 -7.65
Close 1.57 1 Month -0.23 -12.78
Volume 119657 1 Year -0.63 -28.64
52 Week High 2.21 | 52 Week Low 1.59
 
MC Spain Most Active Stocks
UBS 0.00 %
SAN 4.53 0.44%
CABK 5.46 0.92%
DIA 0.01 0.00%
IAG 2.96 1.72%
TEF 4.26 -1.62%
SAB 1.84 0.55%
IBE 13.32 -0.22%
BBVA 9.25 0.22%
UNI 1.24 0.81%
 
MC Spain Top Gainers Stocks
AMP 0.11 10.00%
AMP 0.11 10.00%
AMP 0.11 10.00%
AMP 0.11 10.00%
AMP 0.11 10.00%
AMP 0.11 10.00%
AMP 0.11 10.00%
AMP 0.11 10.00%
AMP 0.11 10.00%
ADL 0.19 5.56%
 
MC Spain Top Losers Stocks
CDR 0.09 -30.77%
CDR 0.09 -30.77%
CDR 0.09 -30.77%
CDR 0.09 -30.77%
MED 0.69 -19.77%
MED 0.69 -19.77%
MED 0.69 -19.77%
MED 0.69 -19.77%
MED 0.69 -19.77%
MED 0.69 -19.77%
 
 
ORY
Daily Charts		 ORY
Intraday Charts		 Whats New @
Bazaartrend		 ORY
Free Analysis
 
ORY Important Levels Intraday
RESISTANCE1.67
RESISTANCE1.64
RESISTANCE1.62
RESISTANCE1.60
SUPPORT1.54
SUPPORT1.52
SUPPORT1.50
SUPPORT1.47
 
ORY Forecast November 2024
Share
4th UP Forecast1.86
3rd UP Forecast1.77
2nd UP Forecast1.71
1st UP Forecast1.65
1st DOWN Forecast1.49
2nd DOWN Forecast1.43
3rd DOWN Forecast1.37
4th DOWN Forecast1.28
 
ORY Weekly Forecast
4th UP Forecast1.82
3rd UP Forecast1.74
2nd UP Forecast1.69
1st UP Forecast1.64
1st DOWN Forecast1.50
2nd DOWN Forecast1.45
3rd DOWN Forecast1.40
4th DOWN Forecast1.32
 
ORY Forecast2024
4th UP Forecast3.17
3rd UP Forecast2.66
2nd UP Forecast2.34
1st UP Forecast2.02
1st DOWN Forecast1.12
2nd DOWN Forecast0.8
3rd DOWN Forecast0.48
4th DOWN Forecast-0.03
 
 
ORY Other Details
Segment EQ
Market Capital 160395264.00
Sector Healthcare
Industry Biotechnology
Offical website >
 
ORY Address
ORY
 
ORY Latest News
 
Your Comments and Response on Oryzon Genomics S.A
 
ORY Business Profile
Oryzon Genomics S.A., a clinical phase biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for the treatment of oncological and CNS disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, a LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases, as well as other programs at various stages of development. The company was founded in 2000 and is based in Cornellà de Llobregat, Spain. Address: Sant Ferran 74, Cornellà de Llobregat, Spain, 08940
 
© 2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service